PRESS RELEASE published on 02/23/2023 at 13:00, 1 year 8 months ago Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates
PRESS RELEASE published on 02/22/2023 at 22:05, 1 year 8 months ago Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Mela
PRESS RELEASE published on 02/22/2023 at 13:00, 1 year 8 months ago Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
PRESS RELEASE published on 02/17/2023 at 17:00, 1 year 9 months ago Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)
PRESS RELEASE published on 02/16/2023 at 22:05, 1 year 9 months ago Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate
PRESS RELEASE published on 02/02/2023 at 13:00, 1 year 9 months ago Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023
PRESS RELEASE published on 01/30/2023 at 13:15, 1 year 9 months ago Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate
PRESS RELEASE published on 01/17/2023 at 22:05, 1 year 10 months ago Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults
PRESS RELEASE published on 01/09/2023 at 13:00, 1 year 10 months ago Moderna Announces Advances Across mRNA Pipeline and Provides Business Update
PRESS RELEASE published on 01/05/2023 at 22:05, 1 year 10 months ago Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
Published on 11/21/2024 at 13:00, 36 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 36 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 36 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 36 minutes ago Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 36 minutes ago Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension
Published on 11/21/2024 at 12:35, 1 hour 1 minute ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 21 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 6 hours 38 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 16 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 19 hours 51 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 19 hours 51 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 5 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
